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Abstract
Introduction: Soluble immune aggregates bearing intact Fc fragments are effective treatment for a variety of
autoimmune disorders in mice. The better to understand the mechanisms by which Fc-bearing immune complexes
suppress autoimmunity, and to develop a platform for clinical translation, we created a series of fully recombinant
forms of polyvalent IgG2a Fc, termed stradomers, and tested their efficacy in a therapeutic model of collagen-
induced arthritis (CIA) and preventive models of both idiopathic thrombocytopenic purpura (ITP) and graft-versus-
host disease (GVHD).
Methods: Stradomers were created by engineering either the human IgG2 hinge sequence (IgG2H) or the
isoleucine zipper (ILZ) onto either the carboxy or amino termini of murine IgG2a Fc. Multimerization and binding
to the canonical Fc receptors and the C-type lectin SIGN-RI were evaluated by using sodium dodecylsulfate-
polymerase chain reaction (SDS-PAGE) and Biacore/Octet assays. The efficacy of stradomers in alleviating CIA and
preventing ITP and GVHD was compared with “gold standard” therapies, including prednisolone and intravenous
immune globulin (IVIG).
Results: Stradomers exist as both homodimeric and highly ordered sequential multimers. Higher-order multimers
demonstrate increasingly stable associations with the canonic Fcg receptors (FcgRs), and SIGN-R1, and are more
effective than Fc homodimers in treating CIA. Furthermore, stradomers confer partial protection against platelet
loss in a murine model ITP, but do not prevent GVHD.
Conclusion: These data suggest that fully human stradomers might serve as valuable tools for the treatment of
selected autoimmune disorders and as reagents to study the function of Fc:FcR interactions in vivo.
Introduction
Soluble immune complexes containing IgG1 Fc can sup-
press ongoing autoimmunity in a variety of animal models
[1]. For example, OVA-anti-OVA conjugates, aggregated
intravenous immunoglobulin (IVIG) products, and anti-
body-coated liposomes are therapeutically efficacious in
murine models of idiopathic thrombocytopenic purpura
(ITP) and rheumatoid arthritis [2-5]. The translational
relevance of these animal findings is supported by clinical
studies in ITP, in which the therapeutic effects of IVIG
directly correlate with the presence of immune aggregates
in the sera [6], and intramuscular (IM) administration of
anti-D immunoglobulin, containing a high aggregate per-
centage, improves platelet counts even in Rh-negative
patients [7]. Despite data supporting the therapeutic
potential of IgG containing Fc multimers, to the best of
our knowledge, no one has generated and evaluated the
antiinflammatory and antiautoimmune properties of fully
recombinant IgG Fc multimers for potential clinical
application.
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As a precursor to the development of fully recombinant
human IgG1 containing Fc multimers for clinical use, we
sought to identify naturally occurring “multimerization
domains” (MDs) with limited immunogenic potential. In
serum, human IgG2 naturally exists as both monomers
(homodimers) and low-abundance dimers, with dimer for-
mation recognized to depend on the hinge region [8-10].
In this report, we demonstrate that fully recombinant
fusion proteins composed of murine IgG2a Fc and either
the human IgG2H or isoleucine zipper (ILZ) MDs exist as
both monomers (homodimers) and as a surprisingly high
percentage of covalently linked highly ordered multimers.
We called these Fc multimers stradomers to distinguish
them from the naturally occurring homodimeric form of
intact immunoglobulins. These novel fusion proteins can
alleviate collagen-induced arthritis (CIA) and prevent ITP
in murine models, raising the possibility that fully human
variants may have therapeutic potential for the treatment
of a variety of rheumatologic diseases [9,10].
Materials and methods
Mice
We used 6- to 8-week-old, female C57BL/6 mice (Charles
River Laboratories, Wilmington, MA, USA, Catalog 027),
female F1(C57BL/6xDBA/2) (Jackson Laboratories, Bar
Harbor, ME, USA, catalog 100006), FcgR2b-/- (Jackson,
Catalog 002848), and TLR4-/- mice (Stefanie Vogel, Uni-
versity of Maryland) were used [11]. All experiments,
except those contracted to outside vendors, were approved
by the Animal Care and Use Committee of the University
of Maryland School of Medicine. Two contract research
organizations paid by Gliknik, Inc., performed CIA experi-
ments in separate mouse lines. Washington Biotechnology
(Baltimore, MD, USA) used DBA1/J mice for their experi-
ments, and Bolder-BioPATH (Boulder, CO, USA) used
DBA/1OlaHsd mice (Harlan Laboratories, Frederick, MD,
USA).
Generation of stradomer and IgG2a Fc cDNA constructs
The Fc regions of the immunoglobulin sequence were
fused to MDs either by splicing by overlap extension
PCR or by using existing compatible restriction sites [12].
Polymerase chain reaction (PCR) primers were generated
encoding the MD and an overlapping region of either the
C or the N-terminus of the IgG Fc region and used for
fusing the two sequences by PCR. The PCR products
were then cloned into pcDNA3.3 by TA cloning (Invitro-
gen, Carlsbad, CA, USA) and confirmed by sequencing.
Stradomers were transiently expressed in HEK293 cells
after transfection.
Purification of stradomers
Purification was done by using automated chromatogra-
phy (Aktaxpress, GE, Piscataway, NJ, USA) and Hitrap
Mabselect, protein A-derived ligand columns (GE 28-
4082-56), followed by desalting on a HiPrep 26/10 Col-
umn (GE 17-5087-01). Stradomers were separated into
homodimeric and multimeric fractions by using the
standard Aktaxpress purification protocol and a GE
Hiload 16/60 Superdex 200-pg size exclusion column
(GE 17-1069-01).
SDS-PAGE analysis
From 0.5 to 2 μg of nonreduced or reduced sample was
loaded onto Nupage Novex 4-12% Bis-Tris Mini Gels
(Invitrogen, Carlsbad, CA, USA, NPO322BOX) and were
run according to the manufacturer’s protocol (Invitrogen,
IM-8042 Version H). Gels were washed with deionized
water, stained for 30 minutes at room temperature with
Bio-safe Coomassie Dye (Bio-Rad, Hercules, CA, USA,
161-0786), and destained with water.
Surface plasmon resonance
Surface Plasmon resonance (SPR) was performed on a
GE Healthcare Biacore 3000 instrument or on a Biacore
T100. Recombinant mouse FcgRI, FcgRIIb, FcgRIII,
FcgRIV, and SIGN-R1 (RnD Systems; Minneapolis, MN,
USA) were immobilized onto a CM4 (FcgRs) or CM5
(SIGN-R1) chip by amine coupling. Samples were serially
diluted in HBS-EP (running buffer) from 1,000 nM to
0.5 nM and injected at 20 μl/min, followed by a dissocia-
tion phase. Flow cells were regenerated with 1 M MgCl
at 100 μl/min and then washed with HBS-EP (FcgRI
required 10 mM glycine pH 2.0 to regenerate). A blank
flow cell was used as a reference. All samples were run in
duplicate or triplicate. The KD was calculated by using a
1:1 Langmuir kinetic model. Unless otherwise specified,
all reagents were from GE Healthcare (Piscataway, NJ,
USA). Because many of the preparations used in our stu-
dies contained multimers of diverse molecular masses,
we standardized our analysis by assigning a molecular
mass of 50 kDa to homodimer isolates and 150 kDa to all
other protein preparations.
Biolayer interferometry
Biolayer interferometry assay was performed on an Octet
96Red Instrument (ForteBio, Menlo Park, CA, USA)
according to the manufacturer’s instructions (Data Acqui-
sition User Guide 6.4, ForteBio). For binding analysis,
His-tagged mouse FcgRIIb (R&D Systems, Minneapolis,
MN, USA, 1460-CD) and FcgRIII (R&D Systems 1960)
were loaded on anti-penta-His Biosensors (ForteBio
18-5077) at 10 μg/ml in 1× kinetic analysis buffer (Forte-
Bio,18-5032). After sensor-tip loading, protein association
was measured by transfer of tips to preparations of either
the monomeric (concentration 2,000 nM to 62.5 nM) or
multimeric fractions (concentration, 100 nM to 3.13 nM)
in 1× kinetics analysis buffer, and dissociation was
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measured by transfer of sensor tips to 1× kinetics buffer.
Analysis was as described (Data Analysis User Guide
6.4ForteBio). Analysis was standardized, as described ear-
lier by assigning a MW of 50 to homodimers and 150 to
all other protein preparations.
Collagen-induced arthritis model
Collagen-induced arthritis experiments were performed
by two contract research organizations (CROs; Washing-
ton Biotechnology, Inc., Columbia, MD, USA; Bolder
BioPATH Inc., Boulder, CO, USA). All arthritis experi-
ments, except for the dose-response data for 2A-2HC,
were generated by Washington Biotechnology by using
the following protocol: On day 0, DBA1/J mice were
immunized with 50 μl of a 4-mg/ml solution of Type II
bovine collagen (Chondrex, Inc., Redmond, WA, USA,
Cat. 20021) emulsified with an equal volume of complete
Freund’s Adjuvant (Sigma, St. Louis, MO, USA, Cat.
5506). A second vaccination was given on day 21 by
using the same dose of Type II bovine collagen emulsi-
fied with an equal volume of incomplete Freund’s Adju-
vant. Mice were scored daily for signs of arthritis. Each
paw was scored, and the sum of all four scores was
recorded as the Arthritic Index (AI). The maximum pos-
sible AI was 16, as follows: 0, no visible effects of arthri-
tis; 1, edema and/or erythema of one digit; 2, edema and/
or erythema of two joints; 3, edema and/or erythema of
more than two joints; and 4, severe arthritis of the entire
paw and digits, including limb deformation and ankylosis
of the joint. Starting on day 28 (treatment day 0), 10 col-
lagen-immunized mice (all manifesting disease) were
sorted into each of the treatment groups based on aver-
age AI (3.3). AI was measured for 14 treatment days,
after which mice were euthanized. For the positive con-
trol group, mice were dosed orally with 10 mg/kg predni-
solone daily. For the 2A-2HC group, mice were dosed
every fourth day (day 0, day 4, day 8, and day 12) with
400 μg 2A-2HC (17.4 mg/kg). Fractionated 2A-2HC was
given at a lower dose (250 μg, 10.9 mg/kg).
A second contract research organization, Bolder Bio-
PATH Inc. (Boulder, CO, USA), independently generated
dose-response data to 2A-2HC in a CIA model by using a
slightly different protocol. In brief, male DBA/1OlaHsd
(Harlan Laboratories, Frederick, MD, USA) mice were
anesthetized with isoflurane and injected with 150 μl of
Bovine Type II collagen (Elastin Products, Owensville,
MO, USA), in Freund’s complete adjuvant on day 0 and
day 21 (Freund’s complete adjuvant [with supplemental
Mycobacterium. tuberculosis, 4 mg/ml], Difco). On study
days 24 through 27, onset of arthritis occurred, and mice
were randomized to treatment groups. Animals were ran-
domized to a treatment group only after swelling was
obviously established in at least one of four paws (score
of 1 for the paw, minimum mean score of 0.25 for the
animal). Attempts were made to assure approximately
equal mean scores across all groups at the time of enroll-
ment. Treatment was initiated after enrollment (treat-
ment day 0). Mice were treated with intravenous 2A-2HC
given at varying doses (10 mg/kg, 20 mg/kg, and 40 mg/
kg). The first dose was administered on day 0 and then
every fourth day. IVIG was given at a dose of 2 g/kg by
intraperitoneal injection on day 0 and every fourth day.
Dexamethasone was given orally at a dose of 0.2 mg/kg
daily beginning on day 0. During this time, clinical scores
were given for each of the paws (right front, left front,
right rear, left rear) as follows: 0, normal; 1, 1 hind- or
forepaw joint affected or minimal diffuse erythema and
swelling; 2, 2 hind- or forepaw joints affected or mild dif-
fuse erythema and swelling; 3, 3 hind- or forepaw joints
affected or moderate diffuse erythema and swelling; 4,
marked diffuse erythema and swelling, or four digit joints
affected; and 5, severe diffuse erythema and severe swel-
ling of the entire paw, unable to flex digits, or ankylosis,
if present. Under this protocol, the mean score of all four
paw scores, rather than a sum, was used for the scoring
index.
Induction and assessment of ITP
Platelet counts were measured by serial tail-vein nicking
on days 1 through 5. To measure platelet counts, 10 μl
of blood was diluted in 15 μl citrate buffer (0.105 M,///
3.2%). The samples were analyzed for absolute platelet
count on a Drew Scientific HemaVet 950FS hemocyt-
ometer that was standardized daily. Control-group mice
received no pretreatment and no platelet depletion. ITP
mice received only platelet depletion with MWReg30 a-
platelet antibody (BD Biosciences, San Jose, CA, USA).
Mice in the experimental groups received pretreatment
with stradomers, murine IgG2a Fc, or IVIG on day 1,
administered 16 to 24 hours before platelet depletion
with MWReg30 each evening on days 2 through 4 (2 μg
diluted in 200 μl PBS, given intraperitoneally). Mice pre-
treated with murine IgG2a Fc or stradomers received
only a single dose (400 μg intravenous) on day 1. Mice
pretreated with IVIG received daily doses (2 g/kg by
intraperitoneal injection every morning on days 1
through 5).
In some experiments, administration of 2A-2HC on day
1 caused an initial decrease in platelet count before admin-
istration of MWReg30. Therefore, percentage platelet
decrease is shown relative to the baseline measurement on
day 2 by using the formula: % = measured platelet count/
baseline platelet count on day 2. Experiments were done
in replicate, as indicated, and all mice were included in
pooled statistical analysis except for the following: for
experiments testing the efficacy of the homodimeric versus
multimeric fractions of 2A-2HC in preventing ITP, three
replicate experiments were done with six mice per group.
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One mouse in the ITP group was excluded because of
spurious platelet values. Two of 18 mice in the 2A-2HC
group were excluded from day 5 analysis because of equip-
ment failure that prevented measurement of platelet
count.
GVHD model
The GVHD model was previously described [13]. On day
0, BDF1 mice were given 4 × 107 C57BL/6 splenocytes
and lymphocytes by tail-vein injection. Mice received no
treatment, IgG2a Fc, or 2A-2HC (both given at 400 μg IV)
on day 0 and day 4. In the preventive study, 2A-2HC was
administered before adoptive transfer of B6 splenocytes
and lymphocytes. On day 9, donor anti-host CTL activity
was tested by 51Cr-release assay against H2d-expressing
P815 cells (positive target) and EL4s that do not express
H2d (negative control).
Injection of opsonized red blood cells (oRBCs)
One day before injecting oRBCs, mice were given either 40
mg of IVIG by intraperitoneal injection, 400 μg of murine
IgG2a Fc by intravenous injection, or 400 μg of 2A-2HC
by intravenous injection. Fluorescence-labeled oRBCs
were generated as described by Song et al. (2003) [14].
Erythrocytes were then washed 3 times with PBS and
resuspended in 5 ml of PBS. Mice were given tail-vein
injections of 200 μl of oRBCs. Mice were then bled by tail-
vein nicking at 3, 30, 60, 90, and 165 minutes after injec-
tion. Blood (10 μl) was collected into a tube containing an
equal volume (10 μl) of 1% EDTA in PBS. After mixing,
1 μl of the sample was diluted in 300 μl of FACS buffer
and used for flow cytometry. The percentage of PKH26-
labeled oRBCs in circulation was measured with flow cyto-
metry. The percentage of fluorescent erythrocytes at the
3-minute time point was considered the baseline (100%).
Statistics
Statisticians had access to all primary data. For the platelet
data, Wilcoxon rank-sum tests were used to compare per-
centages between groups. For the Arthritis Index data, lin-
ear mixed-effects models with either one or two slopes
were used to compare the Arthritis Index over time
between groups. For the platelet and the RBC data, per-
centages of baseline values were calculated for each post-
baseline time point and presented in the plots as means ±
SEM. Wilcoxon rank-sum tests were used to compare per-
centages between groups at some later time points at
which we expected differences to have developed between
groups (days 4 and 5 for platelet data, and 60 minutes,
90 minutes, and 165 minutes after injection for RBC data).
Unless otherwise indicated, all comparisons reported were
made against the diseased with no-treatment group (ITP,
CIA, or injected oRBCs with no pretreatment). Bonferro-
ni’s correction was used for significance where multiple
comparisons were made, with the intended number of
comparisons reported.
Results
Stradomers exist as highly ordered multimers that can be
fractionated by size
To evaluate the potential of the IgG2 hinge as an MD, we
created cDNA constructs in which the hinge region of
human IgG2 was linked to either the carboxy (2A-2HC) or
amino (2A-2HN) termini of murine IgG2a Fc. In parallel,
we developed compounds with the previously described
ILZ at the carboxy (2A-ILZC) or amino termini (2A-ILZN)
(Figure 1A) [15]. None of these fusion proteins contains
an Fab region. We named the resultant proteins “strado-
mers” to distinguish them from naturally occurring homo-
dimeric and multimeric immunoglobulins.
On purification, analysis of these compounds with
SDS-PAGE revealed that both of the stradomers contain-
ing the isolated IgG2 hinge region exist as homodimers
(50 kDa) and as highly ordered multimers, which occur
at a far higher percentage than found with recombinant
IgG2a Fc (Figure 1B). The fact that these multimers are
present under denaturing, but not reducing conditions,
suggests that they are covalently linked. Although both
ILZ compounds were also composed of homodimers and
multimers, the presence of higher-order multimers was
less than that observed for the 2H stradomers. This lack
of higher-order multimers was most pronounced for the
2A-ILZC protein. As expected, recombinant IgG2a Fc
was present at the appropriate size for a homodimer
(45 kDa). In addition, a less-intense band, which likely
represents a multimer, was present at approximately 90
kDa (Figure 1B).
As a first step toward characterizing the function of
these stradomers, we isolated the homodimeric and multi-
meric forms of one representative stradomer, 2A-2HC.
SDS-PAGE analysis of the resultant fractions revealed that
the higher-order multimers could be separated from the
homodimeric fractions with a relatively high degree of
purity (Figure 1C, D). These data demonstrate that incor-
poration of a novel human IgG2H MD onto either the
amino or carboxy terminus of mouse IgG2a Fc results in a
fusion protein, which forms highly ordered Fc multimers
that can be fractionated according to Fc valency.
Stradomer binding to low-/intermediate-affinity canonic
FcgRs and SIGN-R1 directly correlates with the degree
of multimerization
Low-/intermediate-affinity FcgRs, including FcgRIIb,
FcgRIII, and FcgRIV, are recognized to form more-stable
associations with Fc-bearing immune complexes than
with nonmultimerized Fc of the appropriate isotype
[16]. Furthermore, the mechanisms by which both IVIG
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and Fc-bearing immune complexes mediate tolerance
are reported to depend on engagement of selected low/
intermediate receptors [2]. Based on these data, we
sought to determine whether these fully recombinant
stradomers could effectively engage the canonic FcgRs
and to correlate the stability of these interactions with
Fc valency.
Evaluation of stradomer interactions with murine
FcgRs by surface plasmon resonance (SPR) revealed
that, in comparison to the transient associations
observed with recombinant IgG2a Fc, the 2A-2HC, 2A-
2HN, and 2A-ILZN proteins formed stable interactions
with FcgRI, FcgRIIb, FcgRIII, and FcgRIV. The interac-
tions of 2A-ILZC with these receptors were similar to
those of IgG2a Fc, consistent with the lack of highly
ordered multimer formation. Additionally, based on
reports that suggest that the C-type lectin, SIGN-R1,
regulates the antiinflammatory effects of IVIG through
specific interactions with a-2,6-sialylated Fcs [17], we
also evaluated the ability of the stradomers to interact
with SIGN-R1. The ability of unfractioned stradomers
to bind SIGN-R1 was superior to that of IgG2a Fc but
more limited in comparison with the canonic receptors,
and the stability of these associations was generally less
than that observed for interactions with the canonic
FcgRs (Figure 2A, Table 1).
To place our findings in context with previous reports
demonstrating that the valency of Fc-containing com-
pounds affects interactions with their cognate receptors
[16], we evaluated binding of the individual fractions of
2A-2HC with FcgRIIb, FcgRIII, and SIGN-R1 by SPR (Fig-
ure 2B), and with FcgRIIb and FcgRIII by Biolayer Inter-
ferometry (see Additional File 1, Figure S1). Consistent
with the findings of others, higher-order multimers of
2A-2HC formed more-stable interactions with both
FcgRIIb and FcgRIII than did the smaller isolates. Unex-
pectedly, the higher-order isolates also bound with
greater avidity to SIGN-R1, suggesting that this may be a
low- to moderate-affinity receptor. Taken in concert,
these data demonstrate that fully recombinant strado-
mers can recapitulate the binding avidity of Fc-bearing
immune complexes.
Figure 1 Stradomers form highly ordered multimers, which can be fractionated by size. (A) Stradomers consist of the murine IgG2a hinge, CH2,
and CH3 domains (abbreviated as 2A), linked to a multimerization domain (MD) at the carboxy (C) or amino (N) terminus. The MD is either the human
IgG2 hinge (2H) or an isoleucine zipper (ILZ). (B) SDS-PAGE of the stradomer proteins. Homodimeric 2A-2HC bands have a molecular mass of 55 kDa.
Multimeric bands have a mass of 150 kDa or more. (C) The 2A-2HC protein was fractionated on a GE Highload Phenyl Sepharose High-Performance
column (GE 17-1066-01) by using a standard protocol. The sample was run at a rate of 3 ml/min, and 2-ml fractions were collected. UV spectrometry at
280 nm was used to quantify protein in each fraction, yielding a histogram readout characterized by peaks representing the different fractions.
(D) SDS-PAGE of unfractionated 2A-2HC, fraction I, fraction II, and fraction III. Homodimeric 2A-2HC bands have a mass of 55 kDa. Multimeric bands are
higher at ≥ 100 kDa.
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Stradomers can effectively treat collagen-induced
arthritis
To begin to understand the function of the stradomers
in vivo, we used a CIA model thought to recapitulate
closely many of the essential features of rheumatoid
arthritis. CIA studies were performed at two different
contract research organizations, with selected experi-
ments blinded to the test articles. Animals receiving the
drug experienced only limited toxicities, the major man-
ifestations of which included transient piloerection and
a brief period of lethargy. In the CIA model, all strado-
mers showed pronounced therapeutic effects in treating
CIA (P < 0.0001 for 2A-2HC, 2A-2HN, and 2A-ILZC;
P = 0.0021 for 2A-ILZN) (Figure 3A). Interestingly, the
2A-ILZC fusion protein, which forms limited higher-
order multimers in solution, was able to alleviate CIA
significantly (P < 0.0001). Although IVIG was also thera-
peutic, the kinetics and potency of this effect were
delayed and less robust than those observed with 2A-
2HC (P < 0.0001 for IVIG) (Figure 3B).
Figure 2 The ability of stradomers to engage canonic FcgRs and SIGN-R1 correlates with their degree of multimerization. Recombinant
mouse FcgRI, FcgRIIb, FcgRIII, FcgRIV, and SIGN-R1 were immobilized onto a CM4 (FcgRs) or CM5 (SIGN-R1) chip by amine coupling. The stradomers
and Fc-modified antibodies were injected over the immobilized receptors. The SPR sensorgrams depict the association and dissociation phases of
the injected proteins with the receptors. Increased affinity is indicated by higher relative RU. (A) SPR sensorgrams of stradomers binding to the
canonic FcgRs and the C-type lectin SIGN-R1 are shown. (B) The 2A-2HC stradomer was separated into multimer-enriched (I) and homodimer-
enriched (III) fractions. SPR sensorgrams indicate binding of IgG2a Fc, IVIG, whole 2A-2HC, fraction I, and fraction III to FcgRIIb, FcgRIII, and SIGN-R1.
Table 1 Binding analysis of 2H- and ILZ-based stradomers to individual FcRs
FcgRI FcgRIIb FcgRIII FcgRIV SIGN-R1
IgG2a Fc 17.4 (4.07) 289 (1.48) 248 (2.9) 27.8 (25.4) n.s.a
2A-ILZN 6.71 (52.9) 3.8 (51.3) 2.3 (85.4) .46 (88.3) 134 (0.43)
2A-ILZC 63.4 (7.62) 455 (11) 151 (16.1) 63.6 (20) 43.9 (0.77)
2A-2HN 16.3 (7.62) 3.4 (12.1) 4.4 (24.9) 7.6 (11.3) 109 (0.11)
2A-2HC 9.12 (9.97) 3.3 (29.2) 4.2 (40.6) 3.03 (18.9) n.s.
a
KD (left, in nM), and c2 (right, in parenthesis). aInsufficient binding to calculate KD.
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Based on the finding that 2A-ILZC, which had a low per-
centage of multimers, can alleviate CIA, we isolated the
homodimeric and multimeric fractions of 2A-2HC to
determine the importance of Fc multimers in this model.
Whereas the homodimeric fraction of 2A-2HC demon-
strated some therapeutic benefit in alleviating CIA, this
treatment effect was less robust than that observed with
the multimeric fraction (P < 0.0001 for homodimeric and
multimeric fractions of 2A-2HC) (Figure 3C). These find-
ings are consistent with the idea that Fc homodimers may
have some therapeutic benefit in selected models based on
their ability to block transiently FcgRs and to decrease the
half-life of pathogenic autoantibodies by competing for
binding with the neonatal receptor (FcRn) [18]. It is also
the case that murine IgG2a Fc, unlike human IgG1 Fc,
autodimerizes (Figure 1B), which may contribute to the
activity of IgG2a Fc “homodimers” in murine models.
Finally, to understand whether our findings were dose
dependent, we had a third-party CRO blinded to dose
and control evaluate doses of 10, 20, and 40 mg/kg in
the CIA model. Our data indicate that a dose-dependent
difference exists in potency (Figure 3D). These findings
suggest that although a dose-response exists to the stra-
domers in CIA, a therapeutic threshold may exist.
Stradomers can effectively prevent idiopathic
thrombocytopenic purpura
To extend our findings, we evaluated the therapeutic uti-
lity of stradomers in murine models of ITP and graft-ver-
sus-host disease (GVHD). The ITP model differs from
Figure 3 Stradomers effectively treat CIA. Stradomers were tested in a treatment model of murine CIA. Treatment was initiated after mice
had an average arthritis score of 3.3. Each paw was scored individually for arthritis (0 to 4), and the sum of all four paws was used as the score
for the animal (maximum of 16). The positive treatment control for these experiments was oral prednisolone at 10 mg/kg daily. (A) Direct
comparison of stradomers in the CIA model. (B) Comparison of 2A-2HC efficacy against IVIG. (C) Comparison of the 2A-2HC homodimeric and
multimeric fractions. (*Significant compared with no treatment, with Bonferroni correction). The 2A-2HC dose-response experiments were
performed by a separate contract organization that used a different arthritis-scoring system. Each paw was scored on a scale of 0 to 5. The
average of all four paws (rather than the sum) was used as the score for the animal. (D) Dose-response curve of 2A-2HC. Treatment control for
this experiment was oral dexamethasone at 0.2 mg/kg daily.
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CIA in that anti-platelet antibody is directly administered
to the host, and thus is not dependent on secondary anti-
body development as a result of antigen priming/boost-
ing. In the ITP model, a single intravenous dose of
400 μg of 2A-2HC protected mice against platelet loss
(P < 0.0001, days 4, 5), whereas recombinant murine
IgG2a Fc was less effective (P = 0.0145; P = 0.178 days 4,
5, neither significant with the Bonferroni correction)
(Figure 4A). Fractionation of 2A-2HC revealed that the
observed protective effects were primarily attributable to
the multimeric (P < 0.0001, days 4, 5) rather than the
homodimeric fraction (P = 0.0093; P = 0.140 days 4, 5,
neither significant with the Bonferroni correction)
(Figure 4B). Consistent with previous mouse ITP preven-
tion studies, daily high-dose administration of IVIG pro-
vided nearly complete protection against platelet loss.
Functionally, although 2A-ILZN conferred significant
protection from MWReg30-induced platelet depletion
(P = 0.0056; P = 0.0001; days 4, 5), unlike that in the CIA
model, the 2A-ILZC protein at the same dose was not
effective (P = 0.80; P = 0.76 days 4, 5) (Figure 4C).
In some, but not all, individual experiments, we
observed a significant platelet decrease 16 to 24 hours
after infusion of 2A-2HC, before the administration of
MWReg30 (see Additional File 2, Figure S2A). Detailed
studies in TLR-4-/- mice, which lack the endotoxin recep-
tor [11], revealed that this effect is not due to contami-
nating endotoxin. However, flow cytometry-based
platelet-binding studies suggest that these observations
may be secondary to the ability of 2A-2HC to bind to pla-
telets, resulting in their transient sequestration (see Addi-
tional File 2, Figure S2B). Taken in concert, our findings
confirm that the protection conferred by recombinant
IgG2a Fc fusion compounds against the development of
ITP is not restricted to an individual MD or MD location,
and suggest that protection may be related to the percen-
tage and/or size of multimers in the preparation, as is the
case with IVIG aggregates [4,16].
Importantly, unlike ITP and CIA, in which antibody
responses are recognized to play an important role in
disease pathogenesis, 2A-2HC was not effective in either
the prevention or the treatment of GVHD (see Addi-
tional File 3, Figure S3). These differences in therapeutic
utility between model systems might be explained by
the fact that this GVHD model is primarily T-cell
mediated, a fact that may be exploited in future studies
as a means to determine the mechanisms by which stra-
domers mediate their biologic effects [13].
Figure 4 Stradomers effectively prevent ITP. (A) Mice were pretreated with IgG2a Fc, 2A-2HC, or IVIG on day 1 before platelet depletion with
MWReg30. Day 2 platelet counts before MWReg30 administration were considered baseline (100%) (*Significant with Bonferroni correction for
the four comparisons indicated; n = 11 to 12 per group pooled from two separate experiments). (B) 2A-2HC was fractionated into homodimer-
enriched (fraction III) and multimer-enriched (fraction I) fractions and tested in the ITP model (*significant with Bonferroni correction for the six
comparisons indicated; n = 12 to 18 per group pooled from three experiments, two testing unfractionated 2A-2HC, fraction I, and fraction III, and
one testing only unfractionated 2A-2Hc and fraction I). (C) The different stradomers were directly compared in the ITP model. (n = 11 to 12 mice
per group, pooled from two separate experiments. *Significant with Bonferroni correction).
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2A2HC inhibits depletion of circulating opsonized RBCs
Our data indicate that stradomers alleviate CIA and pre-
vent ITP, suggesting that they may represent an advance
toward a recombinant analogue of IVIG. The primary
hurdle to creating a fully recombinant IVIG is the
absence of a clear mechanism of action. Specifically,
IVIG is postulated to mediate its antiinflammatory effects
through multiple mechanisms, including, but not limited
to, (a) saturating the neonatal receptor, FcRn, so that
pathogenic autoantibodies are more rapidly cleared from
the circulation; (b) binding to SIGN-R1/DC-SIGN and/or
the activating FcgIIIa receptor, with subsequent upregula-
tion of the FcgRIIb inhibitory receptor; and (c) competi-
tive inhibition of Fcg receptor signaling [19-21]. Further
complicating matters are the facts that these mechanisms
are not mutually exclusive and that the therapeutic
effects of IVIG may prove to be disease specific.
It has been postulated that IVIG-mediated protection
against ITP is partly due to its capacity to saturate the
reticuloendothelial system (RES), preventing phagocytosis
of autoantibody opsonized platelets. To evaluate this pos-
sibility further, we tested the ability of 2A-2HC to block
the RES, by using an opsonized RBC (oRBC) depletion
model [22]. Our findings reveal that, like IVIG, 2A-2Hc
inhibits the removal of oRBCs from the circulation, indi-
cating that 2A-2HC likely interferes with the RES func-
tion (Figure 5A). Furthermore, because these RBCs were
opsonized ex vivo, our data suggest that the function of
2A-2HC in ITP cannot solely be attributed to blockade of
the FcRn, which has the potential to decrease the half-life
of the MWReg30 anti-platelet antibody used in our ITP
model [23].
2A-2HC protection requires FcgRIIb
Next, we sought to define the role of the inhibitory
FcgRIIb receptor in 2A-2HC-mediated protection
against ITP. The decision to interrogate FcgRIIb was
based on previous studies that have clearly documen-
ted that this receptor is necessary for the protective
effects of IVIG in ITP models [24,25]. By using the
same strain of FcgRIIb-/- mice studied by Siragam and
colleagues [25], we observed a baseline increase in the
hematocrit and a decrease in the platelet counts of
FcgRIIb-/- mice, which limits the dynamic range of the
Figure 5 The RES and FcgRIIb are relevant to stradomer-mediated protection against ITP. (A) Mice were pretreated with 2A-2Hc or IgG2a
Fc for 1 day before injection of fluorescently labeled, opsonized red blood cells (oRBCs) to test whether pretreatment protects against clearance
of circulating oRBCs by the RES. Data shown as percentage-labeled oRBCs/percentage-labeled oRBCs at 3 minutes × 100 (*Significant with
Bonferroni adjustment for the six comparisons indicated; n = 12 mice/group pooled from two separate experiments including these specific
treatment groups). (B) To determine whether the stradomer-mediated protection against ITP in mice is dependent on FcgRIIb, 2A-2HC and
2A-ILZN were tested simultaneously in C57/Bl6 mice with functional FcgRIIb (left) and in FcgRIIb
-/- mice (right) (*Significant with Bonferroni
adjustment for the six comparisons indicated. N = 17 to 18 mice per group, except 2A-ILZN (n = 6), pooled from three separate experiments,
one of which included the 2A-ILZN stradomer).
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ITP assay (see Additional File 4, Figure S4). Consistent
with the findings of other investigators, our data convin-
cingly demonstrate that FcgRIIb is required for the pro-
tective effects of IVIG in a model of ITP (Figure 5B)
[24,25]. Our data also suggest that 2A-2HC- and
2A-ILZN-mediated protection against ITP is likely
dependent on FcgRIIb binding, as neither agent con-
ferred statistically significant protection against platelet
loss in FcgRIIb-/- mice (Figure 5B). Importantly, the
reduced range of this assay introduces a potential source
of bias, which mandates caution when interpreting these
data.
Discussion
Our data demonstrate that we have created recombinant
stradomers that are capable of treating a murine model
of arthritis and preventing the development of ITP.
Although other investigators have shown the utility of
Fc-bearing immune complexes in murine models of auto-
immunity [1,2,26,27], to the best of our knowledge, this is
the first report to describe the generation and production
of fully recombinant Fc multimers. The recombinant nat-
ure of these fusion proteins will likely facilitate clinical
translation with Fc isotype-appropriate human analogues.
Furthermore, we show for the first time that the IgG2H
can be used as an MD. Based on its limited size, and its
existence as a normal component of human IgG2, this
peptide may have broad utility for protein multimeriza-
tion. Finally, because stradomers can be generated on
species-specific Fc backbones and can be readily fractio-
nated by size, they may have value both in defining how
Fc:FcgR interactions modulate inflammation and in act-
ing as controls for antibody-based studies in vivo.
Whereas other investigators have laid the groundwork
for the use of Fc-bearing aggregates in the treatment of
autoimmune diseases [2], to the best of our knowledge,
no one has generated fully recombinant Fc multimers
with therapeutic intent. To accomplish this task, we
sought to identify low-molecular-weight peptides that
could induce Fc multimerization. Human IgG2 exists as
a small percentage of dimers (dimers of the natural
homodimer) in sera, and this dimerization is dependent
on the hinge region [8-10]. Based on this knowledge, we
postulated that by engineering this human IgG2H
sequence onto the amino or carboxy terminus of mouse
IgG2a, we could generate fully recombinant Fc multimers.
SDS-PAGE analysis revealed that the resultant 2A-2H
proteins exist as highly ordered multimer bands that can
be fractionated by size. In comparison with the ILZ-based
stradomers, the degree of multimerization was higher for
the IgG2H-bearing fusion proteins. Based on previous
work demonstrating the import of the low-affinity canonic
FcgRs and SIGN-R1 in modulating the antiinflammatory
and antiautoimmune effects of IVIG and/or immune
complexes comprising Fc regions, we initially sought to
understand how stradomers interacted with these recep-
tors [2,17,24,25,28,29]. Selected stradomers demonstrate
strong interactions with the low-/intermediate-affinity
FcgRs, the stability of which are directly related to their
degree of multimerization. Surprisingly, the multimeric
fraction of 2A-2HN displayed a higher affinity for SIGN-
R1 than its homodimeric analogue, suggesting that SIGN-
R1 may be a low-affinity receptor for IgG2a.
To evaluate the function of these stradomers in vivo,
we compared their efficacy with “gold standard” therapies
(that is, prednisolone, dexamethasone, and IVIG), in
three unique models of autoimmunity. The stradomers
evaluated herein contained a murine IgG2a Fc backbone
without any Fab fragment, limiting the potential for
interspecies cross-reactivity to either the human IgG2
hinge sequence and/or conformational Fc changes
induced by this peptide. Stradomer administration was
associated with minimal toxicity, the primary manifesta-
tions of which were transient piloerection and a brief
period of lethargy. In the CIA model, stradomers demon-
strated therapeutic efficacy in a dose-dependent fashion.
Interestingly, although IVIG partially ameliorated CIA,
the kinetics and potency of this response differed from
that observed with 2A-2HC. These findings are consistent
with the knowledge that IVIG has variable therapeutic
efficacy in rheumatoid arthritis [30] and provide a ratio-
nale for evaluating fully recombinant Fc multimers in
this disease.
The fact that clinical benefit in both CIA and ITP was
observed with stradomers composed of two unique MDs
suggests that our findings are not specifically related to
the multimerization peptide. Consistent with previous
reports describing the mechanism of IVIG in ITP models,
stradomer-mediated protection against platelet loss may
in part be attributable to saturation of the RES, and it
requires FcgRIIb [24,25,31]. Importantly, based on our
finding that FcgRIIb-/- mice have lower platelet counts at
baseline than do wild-type C57/Bl6 mice, the dynamic
range of the ITP assay is reduced, and these data must be
interpreted with caution. Furthermore, unlike the ITP
model, in which multimerization was required for protec-
tion against platelet loss, the homodimeric fraction of
2A-2HC demonstrated therapeutic efficacy in CIA. How-
ever, the potency of the homodimeric fraction was less
than that observed for the isolated multimers. These data
suggest that the mechanisms through which stradomers
mediate their therapeutic effects could be distinct in
these two model systems.
Based on their efficacy in animal models of CIA and
ITP, the human analogues of these stradomers hold pro-
mise for the amelioration of selected human autoim-
mune diseases. In addition, we hypothesize that because
of its small size and existence as a natural component of
Jain et al. Arthritis Research & Therapy 2012, 14:R192
http://arthritis-research.com/content/14/4/R192
Page 10 of 12
human IgG2, the human IgG2 hinge peptide will have
broad utility as a protein MD with limited associated
immunogenicity. Finally, although our study was not
designed to provide detailed mechanistic insights into
the means by which Fc multimers ameliorate autoim-
munity, stradomers, and the isolated fractions thereof,
have the potential to serve as a platform to define the
mechanisms by which Fc:FcgR interactions regulate
inflammation as species-specific controls for mAb stu-
dies in vivo.
Conclusions
This study demonstrates that fully recombinant forms of
murine IgG2a Fc containing unique multimerization
domains, termed stradomers, have the capacity to allevi-
ate CIA and to prevent ITP in mice. Stradomers form
multimeric fractions in solution that are comparable to
the naturally occurring aggregates found in IVIG.
Furthermore, they demonstrate strong interactions with
the low-/intermediate-affinity FcgRs, the stability of
which are directly related to their degree of multimeri-
zation. Fully humanized versions of these unique pro-
teins may have translational applications for treating
arthritis and other selected autoimmune diseases.
Additional material
Additional file 1: Figure S1, 2A-2HC multimer size correlates with
binding stability to FcgRIIb and FcgRIII. This figure shows Octet
biosensor assay data demonstrating that stradobody multimerization
results in more stable associations with FcgRIIb and FcgRIIIa.
Additional file 2: Figure S2, 2A-2HC can cause an initial decrease in
platelet count before platelet depletion with MWReg30 that may
be the result of platelet sequestration by 2A-2HC. This figure
demonstrates that 2A-2HC, in some experiments, caused an initial
decrease in platelet count before administration of the platelet-depleting
antibody MWReg30.
Additional file 3: Figure S3, 2A-2HC does not prevent graft-versus-
host disease. This figure demonstrates that 2A-2HC cannot prevent T-
cell-mediated graft-versus-host disease in a murine model.
Additional file 4: Figure S4, The FcgRIIb-/- and “wild type” C57/BL6
have differing baseline platelet and red blood cell counts. This figure
demonstrates that FcgRIIb-/- and “wild type” C57/BL6 have differing
baseline platelet counts, which could potentially affect the dynamic
range of ITP assay in FcgRIIb-/- mice.
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